PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241305700 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Jun Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation General Project of Jiangxi, Jiangxi Provincial Health Department Project, Training Program for Academic and technical leaders in major disciplines in Jiangxi Province.
Abstract (Originalsprache)
Background
For advanced hepatocellular carcinoma (HCC), sorafenib remains the established therapy. PD-1/PD-L1 inhibitors plus antiangiogenic drugs (PIAD) as a new therapeutic approach for advanced HCC is still a subject of clinical debate regarding whether they offer improved treatment outcomes. This study was conducted to compare the two treatments in terms of antitumor efficacy and safety.
Methods
Randomized controlled trials (RCTs) comparing PIAD and sorafenib for advanced HCC were retrieved from six databases. Survival (overall survival [OS] and progression-free survival [PFS]) were the main outcomes measured. Secondary endpoints included responses, adverse events (AEs), and effects on quality of life.
Results
Seven studies based on four RCTs (CARES-310, COSMIC-312, IMbrave150, and ORIENT-32) were included. The PIAD group exhibited better OS (hazard ratio [HR]: 0.69, 95% confidence interval [CI]: [0.53, 0.89], P = 0.005), and PFS (HR: 0.60, 95% CI: [0.53, 0.67], P < 0.00001). The survival advantages of OS and PFS were confirmed in almost all subgroups. The PIAD group exhibited higher OS rates at 6–18 months and PFS rates at 6–12 months. Additionally, the objective response rate, disease control rate, complete response, and partial response were higher in PIAD group. The PIAD group had a delayed decline in quality of life, physical functioning, and role functioning. However, the PIAD group experienced more grades 3–5 and serious AEs, along with treatment discontinuation, dose reduction, and dose interruption.
Conclusions
PIAD appears to be better than sorafenib for advanced HCC with better survival and responses. However, its higher rate of AEs requires cautious attention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
ORCID-Profile: Tiande Liu
Förderung
- Natural Science Foundation General Project of Jiangxi
- Jiangxi Provincial Health Department Project
- Training Program for Academic and technical leaders in major disciplines in Jiangxi Province
Zitieren
APA
Li, J., Liao, C., Liu, Z., Xiong, H., Cai, J., & Liu, T. (2024). PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241305700
Vancouver
Li J, Liao C, Liu Z, Xiong H, Cai J, Liu T. PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241305700
BibTeX
@article{Li2024,
author = {Li, Jun and Liao, Chun and Liu, Zhaohui and Xiong, Hu and Cai, Jing and Liu, Tiande},
title = {PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241305700}
}
EUVIMED